CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) today announced receipt of a CE mark certificate for the INTERCEPT Blood System for plasma. This allows Cerus to market the plasma system throughout the European Union. As part of the regulatory transition from Baxter to Cerus, the CE mark certificate for the platelet system has been transferred to Cerus from Baxter. In addition, Cerus received ISO 13485 certification, allowing Cerus to sell the INTERCEPT Blood System for platelets and plasma under its own label.
